Literature DB >> 34426076

Prognostic significance of preoperative PNI and CA19-9 for pancreatic ductal adenocarcinoma: A multi-institutional retrospective study.

Shinji Itoh1, Eiji Tsujita2, Kengo Fukuzawa3, Keishi Sugimachi4, Tomohiri Iguchi4, Mizuki Ninomiya5, Takashi Maeda6, Kiyashi Kajiyama7, Eisuke Adachi8, Hideaki Uchiyama9, Tohru Utsunomiya10, Yasuharu Ikeda11, Soichirou Maekawa12, Takeo Toshima13, Noboru Harada13, Tomoharu Yoshizumi13, Masaki Mori13.   

Abstract

BACKGROUND: The aim of this study was to investigate the clinical value of nutritional and immunological prognostic scores as predictors of outcomes and to identify the most promising scoring system for patients with pancreatic ductal adenocarcinoma (PDAC) in a multi-institutional study.
METHODS: Data were retrospectively collected for 589 patients who underwent surgical resection for PDAC. Prognostic analyses were performed for overall (OS) and recurrence-free survival (RFS) using tumor and patient-related factors, namely neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, Prognostic Nutritional Index (PNI), Glasgow Prognostic Score (GPS), modified GPS, C-reactive protein-to-albumin ratio, Controlling Nutritional Status score, and the Geriatric Nutritional Risk Index.
RESULTS: Compared with PDAC patients with high PNI values (≥46), low PNI (<46) patients showed significantly worse overall survival (OS) (multivariate hazard ratio (HR), 1.432; 95% CI, 1.069-1.918; p = 0.0161) and RFS (multivariate HR, 1.339; 95% CI, 1.032-1.736; p = 0.0277). High carbohydrate antigen 19-9 (CA19-9) values (≥450) were significantly correlated with shorter OS (multivariate HR, 1.520; 95% CI, 1.261-2.080; p = 0.0002) and RFS (multivariate HR, 1.533; 95% CI, 1.199-1.961; p = 0.0007). Stratification according to PNI and CA19-9 was also significantly associated with OS and RFS (log rank, P < 0.0001).
CONCLUSIONS: Our large cohort study showed that PNI and CA19-9 were associated with poor clinical outcomes in PDAC patients following surgical resection. Additionally, combining PNI with CA19-9 enabled further classification of patients according to their clinical outcomes.
Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CA19-9; Pancreatic ductal adenocarcinoma; Prognosis; Prognostic nutritional index

Mesh:

Substances:

Year:  2021        PMID: 34426076     DOI: 10.1016/j.pan.2021.08.003

Source DB:  PubMed          Journal:  Pancreatology        ISSN: 1424-3903            Impact factor:   3.996


  6 in total

1.  Prognostic Significance of PNI in Patients With Pancreatic Head Cancer Undergoing Laparoscopic Pancreaticoduodenectomy.

Authors:  Peng Jiang; Xiaocheng Li; Shupeng Wang; Yahui Liu
Journal:  Front Surg       Date:  2022-06-01

2.  Prognostic value of systemic immune-inflammation index in patients with pancreatic cancer: a meta-analysis.

Authors:  Mao Li; Zhenlu Li; Zihe Wang; Chao Yue; Weiming Hu; Huimin Lu
Journal:  Clin Exp Med       Date:  2022-01-13       Impact factor: 5.057

3.  Prognostic Value of Pretreatment Controlling Nutritional Status Score for Patients With Pancreatic Cancer: A Meta-Analysis.

Authors:  Xiaofeng Ma; Weihua Zou; Yu Sun
Journal:  Front Oncol       Date:  2022-01-20       Impact factor: 6.244

4.  Prediction Models for One-Year Survival of Adult Patients with Acute Kidney Injury: A Longitudinal Study Based on the Data from the Medical Information Mart for Intensive Care III Database.

Authors:  Lifang Zhou; Laping Chu; Junqiong Peng; Shenhan Yin; Yafen Yu
Journal:  Evid Based Complement Alternat Med       Date:  2022-07-05       Impact factor: 2.650

5.  Predictive value of the preoperative prognostic nutritional index for postoperative progression in patients with pancreatic neuroendocrine neoplasms.

Authors:  Mengfei Fu; Li Yu; Liu Yang; Yang Chen; Xiao Chen; Qinyu Hu; Hui Sun
Journal:  Front Nutr       Date:  2022-09-08

Review 6.  Prognostic role of the prognostic nutritional index in patients with pancreatic cancer who underwent curative resection without preoperative neoadjuvant treatment: A systematic review and meta-analysis.

Authors:  Pengcheng Zhao; Zuowei Wu; Zihe Wang; Chao Wu; Xing Huang; Bole Tian
Journal:  Front Surg       Date:  2022-09-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.